From Bevital A/S, Laboratoriebygget, Bergen, Norway (AU and ØM); the Section for Cardiology (ERP and ON), Department of Clinical Science (SJPME and PMU), University of Bergen, Bergen, Norway; the Department of Heart Disease (ON) and the Laboratory of Clinical Biochemistry (PMU), Haukeland University Hospital, Bergen, Norway (ON); and the Department of Epidemiology, School for Public Health and Primary Care, Maastricht University, Maastricht, Netherlands (SJPME).
Am J Clin Nutr. 2014 Jul;100(1):250-5. doi: 10.3945/ajcn.114.083196. Epub 2014 May 7.
Plasma concentrations of PL 5'-phosphate (PLP), which is the active coenzyme form of vitamin B-6, are reduced during inflammation. The underlying mechanisms may include altered tissue distribution or increased catabolism via pyridoxal (PL) to pyridoxic acid (PA). Recently, we showed that catabolic enzyme activity could be assessed by substrate product ratios measured in plasma.
We evaluated the ratios PA:PL, PA:PLP, and PA:(PL + PLP) as possible markers of vitamin B-6 catabolism.
Cross-sectional and longitudinal data were derived from the Western Norway B-Vitamin Intervention Trial. We analyzed associations of ratios with inflammatory markers and other clinical variables by using multiple linear regression and partial correlation. In addition, intraclass correlation coefficients (ICCs) were used to assess the ability of plasma indexes to differentiate between subjects.
PA:(PL + PLP) had the highest ICC of all vitamin B-6 metabolites and ratios tested. In regression models, the inflammatory markers C-reactive protein, white blood cell count, neopterin, and kynurenine:tryptophan collectively accounted for 28% of the total and > 90% of the explained variation in PA:(PL + PLP). For individual B-6 metabolites, corresponding numbers were 19-25% and 20-44%, respectively, with vitamin supplement intake, smoking, and kidney function (estimated glomerular filtration rate) as additional predictors. In an analysis of receiver operating characteristics, PA:(PL + PLP) discriminated high inflammatory concentrations with an area under the curve (95% CI) of 0.85 (0.81, 0.89).
Broad-specificity enzymes upregulated to reduce oxidative and aldehyde stress could explain increased catabolism of vitamin B-6 during inflammation. The ratio PA:(PL + PLP) may provide novel insights into pathologic processes and potentially predict risk of future disease.
在炎症期间,PL 5'-磷酸酯(PLP)的血浆浓度降低,PLP 是维生素 B-6 的活性辅酶形式。其潜在机制可能包括组织分布改变或通过吡哆醛(PL)转化为吡哆酸(PA)导致的分解代谢增加。最近,我们表明可以通过在血浆中测量底物产物比来评估分解代谢酶的活性。
我们评估了 PA:PL、PA:PLP 和 PA:(PL + PLP) 比值作为维生素 B-6 分解代谢的可能标志物。
横断面和纵向数据来自于挪威西部维生素 B 干预试验。我们使用多元线性回归和偏相关分析,评估了比值与炎症标志物和其他临床变量的相关性。此外,使用组内相关系数(ICC)评估了血浆指标区分个体的能力。
在所有测试的维生素 B-6 代谢物和比值中,PA:(PL + PLP) 的 ICC 最高。在回归模型中,炎症标志物 C 反应蛋白、白细胞计数、新蝶呤和犬尿氨酸:色氨酸共同解释了 PA:(PL + PLP) 总变异的 28%和超过 90%的可解释变异。对于个别 B-6 代谢物,相应的数值分别为 19-25%和 20-44%,维生素补充剂摄入、吸烟和肾功能(估计肾小球滤过率)是额外的预测因素。在接受者操作特征分析中,PA:(PL + PLP) 区分高炎症浓度的曲线下面积(95%CI)为 0.85(0.81,0.89)。
为了减轻氧化和醛应激而上调的广谱特异性酶可能解释了维生素 B-6 在炎症期间的分解代谢增加。PA:(PL + PLP) 比值可能为病理过程提供新的见解,并可能预测未来疾病的风险。